[HTML] jci.org

[HTML][HTML] Androgen receptor–negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms

ZG Li, P Mathew, J Yang, MW Starbuck… - The Journal of …, 2008 - Am Soc Clin Investig
In prostate cancer, androgen blockade strategies are commonly used to treat osteoblastic
bone metastases. However, responses to these therapies are typically brief, and the …
被引用次数：190 相关文章

Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms

GL Zhi, P Mathew, J Yang, MW Starbuck… - 2008 - notablesdelaciencia.conicet.gov.ar
In prostate cancer, androgen blockade strategies are commonly used to treat osteoblastic
bone metastases. However, responses to these therapies are typically brief, and the …
[HTML] nih.gov

[HTML][HTML] Androgen receptor–negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms

ZG Li, P Mathew, J Yang, MW Starbuck… - The Journal of …, 2008 - ncbi.nlm.nih.gov
In prostate cancer, androgen blockade strategies are commonly used to treat osteoblastic
bone metastases. However, responses to these therapies are typically brief, and the …

Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms

ZG Li, P Mathew, J Yang… - The Journal of …, 2008 - pubmed.ncbi.nlm.nih.gov
In prostate cancer, androgen blockade strategies are commonly used to treat osteoblastic
bone metastases. However, responses to these therapies are typically brief, and the …
[PDF] academia.edu

[PDF][PDF] Androgen receptor–negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms

ZG Li, P Mathew, J Yang, MW Starbuck, AJ Zurita, J Liu… - academia.edu
In prostate cancer, androgen blockade strategies are commonly used to treat osteoblastic
bone metastases. However, responses to these therapies are typically brief, and the …

Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms

GL Zhi, P Mathew, J Yang, MW Starbuck, AJ Zurita… - 2008 - ri.conicet.gov.ar
In prostate cancer, androgen blockade strategies are commonly used to treat osteoblastic
bone metastases. However, responses to these therapies are typically brief, and the …
[PDF] researchgate.net

[PDF][PDF] Androgen receptor–negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms

ZG Li, P Mathew, J Yang, MW Starbuck, AJ Zurita, J Liu… - researchgate.net
In prostate cancer, androgen blockade strategies are commonly used to treat osteoblastic
bone metastases. However, responses to these therapies are typically brief, and the …

Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms

GL Zhi, P Mathew, J Yang… - Journal of …, 2008 - mdanderson.elsevierpure.com
In prostate cancer, androgen blockade strategies are commonly used to treat osteoblastic
bone metastases. However, responses to these therapies are typically brief, and the …

[引用][C] Androgen receptor‐negative human prostate cancer cells induce osteogenesis in mice through FGF9‐mediated mechanisms

ZG Li - J Clin Invest, 2008 - cir.nii.ac.jp
Androgen receptor‐negative human prostate cancer cells induce osteogenesis in mice through
FGF9‐mediated mechanisms | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …

Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms

ZG Li, P Mathew, J Yang, MW Starbuck… - Journal of Clinical …, 2008 - search.proquest.com
In prostate cancer, androgen blockade strategies are commonly used to treat osteoblastic
bone metastases. However, responses to these therapies are typically brief, and the …